Navigation Links
Anastrozole Confirmed Superior in Breast Cancer Prevention
Date:12/14/2007

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated with anastrozole disappears after treatment ends.

Speaking at the Thursday session of the San Antonio Breast Cancer Symposium, Professor John Forbes of the University of Newcastle presented the much-anticipated long-term results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial that compared 5 years of tamoxifen with 5 years of the aromatase inhibitor anastrozole for the treatment of postmenopausal women with invasive breast cancer.

Hormone-responsive breast cancers require estrogen stimulation in order to grow. Tamoxifen, a synthetic variation of estrogen, binds to hormone receptors on hormone-sensitive cancer cells, preventing estrogen from attaching to the cells. Anastrozole, on the other hand, prevents the manufacture of estrogen by body tissues other than the ovaries (e.g., fat cells), so it is useful for the treatment of hormone-sensitive cancers in postmenopausal women whose ovaries are no longer producing estrogen.

Although previous reports at 33 and 68 months demonstrated that anastrozole was more effective, has fewer serious side effects, and was better tolerated than tamoxifen during the period of treatment, it was not known whether the benefits or side effects associated with anastrozole would persist long term after patients were no longer taking the drug.

After 10 years (5 years after the completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrence and metastasis compared with patients who had taken tamoxifen. In fact, the relative benefit of anastrozole actually increased compared with results seen immediately after the completion of treatment.

Most strikingly, the incidence of a new cancer occurring in the other breast was significantly lower at 10 years in women who took anastrozole compared with those who received tamoxifen. Tamoxifen has been approved for several years for use in preventing new breast cancers, and it now appears that anastrozole may be even more effective.

Many patients have been reluctant to begin treatment with anastrozole because of concern about the potential for increased bone loss and risk of fracture that can occur with the use of aromatase inhibitors. It was not known whether these effects would persist after the end of treatment. With the new data presented today, it appears that they do not. Although the incidence of fractures was nearly 30% higher in patients treated with anastrozole while they were taking the drug, that difference disappeared after treatment was completed. In addition, there do not appear to be any other important side effects related to anastrozole treatment at this time.


'/>"/>
SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Game Commission Announces EHD Confirmed in Fayette County
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
(Date:5/4/2017)... 4, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... "Company"), today announced that the Company,s first quarter 2017 ... Thursday, May 11, 2017, and that the Company will ... p.m. PT that afternoon. Management will provide an overview ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel ... created specifically for use in Final Cut Pro X. The business-oriented elements and ... Pixel Film Studios’ ProParagraph Corporate will deliver a professional and distinguished look to ...
(Date:5/21/2017)... ... May 21, 2017 , ... For more than 20 years United ... range of knives and swords, from functional to fantasy. United Cutlery has always been ... modern designs that defy tradition. , Offering a range of weapons and tools built ...
(Date:5/19/2017)... Charlotte, NC (PRWEB) , ... May 19, 2017 ... ... of the Charlotte health community, Queens University of Charlotte recently began recruitment efforts ... The program’s curriculum arms students with the skills, knowledge and expertise to approach ...
(Date:5/19/2017)... ... 19, 2017 , ... The Hill Agencies, a family managed firm that offers ... Central Valley, is announcing a joint charity initiative with the Boys and Girls Club ... camp event. , The Boys and Girls Club of Kern County gives young people ...
(Date:5/19/2017)... ... 2017 , ... As a groundbreaking surgeon on the frontline of prostate cancer ... Early detection of the disease, he says, can make a world of difference. ... stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and its ...
Breaking Medicine News(10 mins):